Table 3.
Multivariate analysis of prognostic factors associated with overall survival.
| Variables | Overall survival | |||||
|---|---|---|---|---|---|---|
| Training cohort | Validation cohort | |||||
| Patients (n=220 ) | P-value | HR (95% CI) | Patients (n=134 ) | P-value | HR (95% CI) | |
| Tumor differentiation, well/moderate/poor | 5/83/132 | 0.039 | 1.346 (1.016-1.783) | 4/53/77 | 0.007 | 1.735 (1.160-2.595) |
| TNM stage, I/ II/ III | 79/111/30 | <0.001 | 1.508 (1.208-1.888) | 50/53/31 | 0.005 | 1.459 (1.118-1.906) |
| CA19-9, < 37/ ≥ 37 U/L | NA | 26/108 | 0.416 | 1.281 (0.705-2.327) | ||
| CEA, < 5/ ≥ 5 ng/mL | 159/61 | 0.414 | 1.155 (0.818-1.630) | 94/40 | 0.079 | 1.491 (0.955-2.328) |
| TBIL, ≤ 20.4/ > 20.4 μmol/L | NA | 56/78 | 0.602 | 0.812 (0.372-1.774) | ||
| ALB, < 35/ ≥ 35 g/L | NA | 40/94 | 0.176 | 0.724 (0.453-1.156) | ||
| GGT, ≤ 60/ > 60 U/L | 104/116 | 0.683 | 1.108 (0.676-1.817) | 45/89 | 0.988 | 1.006 (0.490-2.064) |
| ALP, ≤ 125/ > 125 U/L | 121/99 | 0.488 | 0.814 (0.454-1.457) | 55/79 | 0.355 | 1.434 (0.668-3.075) |
| Glucose, ≤ 5.6/ >5.6 mmol/L | NA | 58/76 | 0.033 | 1.619 (1.041-2.519) | ||
| GAR, ≤ 0.63/ > 0.63 | NA | 28/106 | 0.941 | 0.970 (0.436-2.156) | ||
| APAR, ≤ 2.16/ > 2.16 | 98/122 | 0.004 | 2.086 (1.272-3.423) | 35/99 | 0.038 | 2.175 (1.044-4.533) |
| NLR, ≤ 0.39/ >0.39 | NA | 60/74 | 0.280 | 1.287 (0.814-2.034) | ||
CA19-9, cancer antigen 19-9; CEA, carcino embryonie antigen; TBIL, total bilirubin; ALB, albumin; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; GAR, gamma-glutamyl transpeptidase-to-albumin ratio; APAR, alkaline phosphatase-to-albumin ratio; NLR, neutrophil-to-lymphocyte ratio; HR, hazard ratio; P-value < 0.05 marked in bold font shows statistical significant.